VX-670 for adults with myotonic dystrophy type 1
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This trial tests an experimental drug called VX-670 for adults with myotonic dystrophy type 1 (DM1), a genetic muscle disease. It aims to see if the drug is safe and can help improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of myotonic dystrophy type 1 (DM1) with a genetic test result showing at least 100 CTG repeats.
- Your symptoms must have started after your first birthday.
- You should not have any other medical condition that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests DYNE-101 to see how safe it is and whether it can improve measurable muscle function in people with myotonic dystrophy type 1 (DM1). You may be asked to do several walking and strength tests and undergo heart and breathing screening measurements.
This study is for people who already received VX-670 in a previous trial and want to continue treatment. It will check the drug's long-term safety and how well it works for myotonic dystrophy type 1.
This trial tests an experimental drug called DYNE-101 to see if it can help people with myotonic dystrophy type 1 (DM1). The study aims to improve muscle function and daily life. It is for adults who can walk and stand up from a chair without help.
This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.
This study follows people with myotonic dystrophy type 1 over time to learn more about the condition. It is for people of any age who have genetic confirmation of DM1, whether or not they have symptoms.
This study tests whether remote assessments can track myotonic dystrophy type 1 (DM1) and looks at genetic factors. It aims to find better ways to monitor the disease from home.
Hear when a new Myotonic Dystrophy Type 1 (DM1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.